LDH-mediated autophagic full-chain blockade for Multiple Myeloma treatment by targeting circ_0008255/miR-192-5p/ATG2A axis.
Circ_0008255 is upregulated in multiple myeloma and may play a key role in promoting tumor growth, but its therapeutic implications require further investigation.
Where it sits
this study against the rest of the ghrp-6 corpusSummary and findings
This study investigates the role of circ_0008255 in multiple myeloma (MM) and its potential as a therapeutic target. It was found that circ_0008255 is upregulated in MM patients and correlates with poor prognosis. The authors developed a nanoplatform to deliver siRNA targeting circ_0008255, aiming to block autophagy in MM cells.
Abstract
Multiple myeloma (MM) is an incurable plasma cell malignancy with limited therapeutic options. Although autophagy dysregulation is implicated in MM pathogenesis, its precise regulation, particularly by circular RNAs (circRNAs), is poorly understood. Through clinical RNA sequencing of primary MM patient samples, we identify an autophagy-associated circRNA, circ_0008255, which is markedly upregulated in MM patients and closely correlated with poor disease prognosis. Functional studies reveal that circ_0008255 promotes MM proliferation and tumor growth by enhancing autophagic activity. Mechanistically, it functions as a competitive endogenous RNA for miR-192-5p, leading to elevated expression of the core autophagy protein, autophagy related 2 homolog A (ATG2A). Furthermore, we developed a biomimetic nanoplatform based on layered double hydroxide (LDH) nanosheets coated with myeloma-derived cell membranes for tumor-specific delivery. This system co-delivers siRNA targeting circ_0008255 to suppress autophagosome initiation, while simultaneously leveraging the lysosome-alkalinizing property of LDH to impair autophagosome-lysosome fusion. Together, these actions enforce a synergistic autophagic full-chain blockade, leading to potent antitumor effects in vitro and in vivo. Overall, our study reveals a central regulatory role of circ_0008255 in myeloma autophagy, offering a promising therapeutic paradigm for MM.
Background
This paper addresses the role of autophagy dysregulation in multiple myeloma (MM), a plasma cell malignancy with limited treatment options. Previous research has indicated that circular RNAs (circRNAs) may play a role in cancer pathogenesis, but their specific mechanisms in MM are not well understood. Understanding the regulatory functions of circRNAs like circ_0008255 could provide insights into new therapeutic strategies for MM.
Methods
The study involved clinical RNA sequencing of primary MM patient samples to identify circRNAs associated with autophagy. Functional studies were conducted to assess the role of circ_0008255 in MM proliferation and tumor growth. A biomimetic nanoplatform was developed for tumor-specific delivery of siRNA targeting circ_0008255.
Results
circ_0008255 was found to be markedly upregulated in MM patients, correlating with poor prognosis. The functional studies demonstrated that circ_0008255 enhances autophagic activity, promoting tumor growth. The nanoplatform effectively co-delivers siRNA targeting circ_0008255, leading to suppression of autophagosome initiation.
Interpretation
The findings suggest that circ_0008255 plays a significant role in the regulation of autophagy in MM, which aligns with previous literature indicating the importance of autophagy in cancer progression. However, the clinical significance of these findings is unclear, as the study does not report direct clinical outcomes or effect sizes. Limitations include the lack of clinical trial data and potential confounding factors in the in vitro and in vivo models used.
Key findings
- circ_0008255 is markedly upregulated in MM patients and closely correlated with poor disease prognosis.
- Functional studies reveal that circ_0008255 promotes MM proliferation and tumor growth by enhancing autophagic activity.
- The developed nanoplatform co-delivers siRNA targeting circ_0008255 to suppress autophagosome initiation.
Limitations
- No clinical trial data reported.
- Focus on molecular mechanisms without direct clinical outcomes.
- Potential confounding factors in in vitro and in vivo models.